← Eichor
Condition: Myelofibrosis Mf Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Myelofibrosis Mf

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Pat
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07128381A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK I
Phase 1/Phase 2 · 12 location(s) · iOnctura · NCT06887803MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Phase 1 · 5 location(s) · Prelude Therapeutics · NCT07469891Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis
Phase 2 · 1 location(s) · The University of Hong Kong · NCT06770842CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Phase 1 · 4 location(s) · CERo Therapeutics Holdings, Inc. · NCT06834282Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Resp
Phase 3 · 215 location(s) · Kartos Therapeutics, Inc. · NCT06479135Haplo-HSCT for Myelofibrosis
NA · 1 location(s) · Peking University People's Hospital · NCT06674382Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal
Phase 1/Phase 2 · 19 location(s) · Telios Pharma, Inc. · NCT05280509A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis
Phase 2 · 2 location(s) · Chengdu Zenitar Biomedical Technology Co., Ltd · NCT06457425MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
Phase 2 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT06541249A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemoki
NA · 1 location(s) · Azienda Ospedaliero-Universitaria di Parma · NCT07419178Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia
Phase 2 · 13 location(s) · Grupo Español de Enfermedades Mieloproliferativas Crónicas P · NCT07394153Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Phase 1 · 7 location(s) · Novartis Pharmaceuticals · NCT07340138A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF)
Phase 1 · 21 location(s) · Ajax Therapeutics, Inc. · NCT06343805A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
Phase 3 · 2 location(s) · Chengdu Zenitar Biomedical Technology Co., Ltd · NCT07317700A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Phase 3 · 30 location(s) · Novartis Pharmaceuticals · NCT07357727Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior T
EARLY_Phase 1 · 1 location(s) · University of Kansas Medical Center · NCT06414681A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
Phase 1 · 3 location(s) · Aspera Biomedicines, Inc. · NCT07250646Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Phase 2 · 9 location(s) · Icahn School of Medicine at Mount Sinai · NCT05835466Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibr
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06327100Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Phase 1/Phase 2 · 28 location(s) · Disc Medicine, Inc · NCT05320198Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Phase 1 · 1 location(s) · Marina Kremyanskaya · NCT05025488A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)
Phase 1/Phase 2 · 22 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06122831A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patient
Phase 2 · 2 location(s) · Chengdu Zenitar Biomedical Technology Co., Ltd · NCT07443306
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.